| Name | Title | Contact Details |
|---|
Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.
Vizgen is unlocking the power of spatial biomolecule profiling to bring new insight into biological systems and disease.
SeLux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic.
The Canadian Cancer Research Group is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
R I Analytical Laboratories Inc is a Warwick, RI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.